ToolsGroup Recognized as The Technology Leader in Retail and Supply Chain 2024 SPARK Matrix(TM) Categories by QKS Group
Company earns top ratings for technology excellence and customer impact in the 2024 SPARK Matrix™ for Retail Forecasting and Replenishment and the 2024 SPARK Matrix™ for Global Supply Chain Inventory Optimization
BOSTON, MA / ACCESSWIRE / November 12, 2024 / ToolsGroup, a leading provider of retail and supply chain planning solutions, has been named the technology leader in QKS Group's 2024 SPARK Matrix™ Retail Forecasting and Replenishment and their 2024 SPARK Matrix™ analysis of the Global Supply Chain Inventory Optimization market. QKS Group, a global advisory and research firm, evaluates vendors for its SPARK Matrix™ based on two key criteria: technology excellence and customer impact.
ToolsGroup was named the leader in the 2024 SPARK Matrix™ for Retail Forecasting and Replenishment for its ability to optimize demand forecasting and deliver more strategic pre- and in-season replenishment and allocation strategies in complex retail environments. Leveraging AI and sophisticated demand sensing, ToolsGroup enables real-time optimization of product, placement, channel, price, and timing, helping businesses maximize revenue, margin and profits.
In addition, ToolsGroup was recognized as the leader in the 2024 SPARK Matrix for Global Supply Chain Inventory Optimization for the third consecutive year for its ability to reduce costs, maximize profitability, and meet customer's strategic business goals. The company's AI-driven technologies-in particular probabilistic forecasting, service-driven inventory optimization, and real-time dynamic data unification-empower organizations to achieve or exceed service level targets while right-sizing inventory.
"ToolsGroup set itself apart as a technology leader by providing customers the data-backed insights they need to meet the current and evolving needs of retailers and supply chain professionals," says Avinash Singh, analyst at QKS Group. "Year-on-year revenue growth, strong enterprise segmentation, a compelling vision & roadmap, and industry-specific capabilities gained ToolsGroup the top spot in our analysis."
The QKS Group SPARK Matrix™ offers an in-depth analysis of global market dynamics, major trends, vendor landscapes, and competitive positioning. By providing a competitive analysis and ranking of leading technology vendors, the SPARK Matrix™ delivers strategic insights that help companies assess provider capabilities, differentiate competitively, and understand market positions.
"We are honored to be recognized by QKS as a technology leader in their analysis of the retail and supply chain markets," said Inna Kuznetsova, CEO of ToolsGroup. "Our AI-driven solutions empower business leaders to navigate the unexpected and adapt swiftly to market shifts, enabling them to exceed customer expectations and maximize profitability. ToolsGroup was founded to deliver innovative solutions to supply chain challenges, and that commitment remains at the heart of everything we do."
ToolsGroup is excited to showcase its industry-leading solutions at NRF Retail's Big Show, taking place January 12-14 in New York City. This premier event brings together over 6,200 brands and 45,000 attendees from across the world for three days of learning, collaboration, and discovery. Reserve a time to connect with ToolsGroup at Booth 4043 here.
To view and down either of the QKS Group 2024 SPARK Matrix™ reports, please visit: SPARK MatrixTM Reports: 2024
About QKS Group
QKS Group is a global advisory and consulting firm focused on helping clients achieve business transformation goals with Strategic Business and Growth advisory services. At QKS Group, our vision is to become an integral part of our client's business as a strategic knowledge partner. Our research and consulting deliverables are designed to provide comprehensive information and strategic insights for helping clients formulate growth strategies to survive and thrive in ever-changing business environments.
For more available research, please visit https://qksgroup.com/.
About ToolsGroup
ToolsGroup's innovative AI-powered solutions enable retailers, distributors and manufacturers to navigate through supply chain uncertainty. Our retail and supply chain planning suites empower a new level of intelligent decision-making and unlock powerful business improvements in forecast accuracy, service levels and inventory - delighting customers and achieving financial and sustainability KPIs. Stay in touch with ToolsGroup on LinkedIn, Twitter, and YouTube, or visit www.toolsgroup.com.
Media Contacts:
QKS Group
Shraddha Roy
PR & Media Relations
shraddha.r@qksgroup.com
ToolsGroup
Escalate PR for ToolsGroup
toolsgroup@escalatepr.com
SOURCE: ToolsGroup
View the original press release on accesswire.com
ToolsGroup
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom